Equities

N4 Pharma PLC

N4P:LSE

N4 Pharma PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)0.772
  • Today's Change-0.028 / -3.50%
  • Shares traded1.85k
  • 1 Year change-58.27%
  • Beta-0.7727
Data delayed at least 20 minutes, as of May 20 2024 12:46 BST.
More ▼

Profile data is unavailable for this security.

About the company

N4 Pharma Plc is a United Kingdom-based pre-clinical stage specialist pharmaceutical company. The Company is engaged in developing Nuvec, which is a novel silica nanoparticle technology with patented spiky structure designed to load, protect and deliver nucleic acids (siRNA/DNA/mRNA) intracellularly for use in as gene therapy, cancer therapeutics and vaccines. Nuvec is in the pre-clinical phase, available for licensing to pharmaceutical and biotech partners for nucleic acid product development and is designed to overcome some of the drawbacks of existing delivery systems. It is also engaged in producing LipTide, which is a patented lipid and peptide-based delivery system for nucleic acids that mimics a natural virus for targeted delivery of RNA into cells. The peptide binds payload and targets specific cells while the lipid allows for efficient endosomal release into the cell. The Company's subsidiary includes N4 Pharma UK Limited and Nanogenics Limited.

  • Revenue in GBP (TTM)1.95k
  • Net income in GBP-1.28m
  • Incorporated1979
  • Employees5.00
  • Location
    N4 Pharma PLCWeston House, 1 Bradgate Park ViewDERBY DE73 5UJUnited KingdomGBR
  • Phone+44 13 3269 0061Fax+44 12 7982 1300
  • Websitehttps://www.n4pharma.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
N4P:LSE since
announced
Transaction
value
Nanogenic Solutions LtdDeal completed28 Sep 202328 Sep 2023Deal completed-44.86%--
Data delayed at least 20 minutes, as of May 20 2024 12:46 BST.

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Ovoca Bio PLC0.00-2.00m590.07k5.00590.07k5.00
Voyager Life PLC314.00k-1.10m630.13k28.00630.13k28.00
Nuformix PLC0.00-436.95k1.52m2.001.52m2.00
Oxford Cannabinoid Tchnlgs Hldngs PLC0.00-4.24m1.69m7.001.69m7.00
ReNeuron Group Plc249.00k-5.07m1.93m34.001.93m34.00
N4 Pharma PLC1.95k-1.28m2.15m5.002.15m5.00
Hellenic Dynamics PLC-100.00bn-100.00bn2.53m25.002.53m25.00
ValiRx Plc9.60k-2.04m2.91m8.002.91m8.00
TheraCryf PLC838.00k-3.35m3.21m7.003.21m7.00
Fusion Antibodies PLC1.58m-2.84m3.24m50.003.24m50.00
IXICO PLC6.67m-1.18m3.57m89.003.57m89.00
BSF Enterprise PLC12.94k-1.50m4.91m4.004.91m4.00
Data as of May 20 2024. Currency figures normalised to N4 Pharma PLC's reporting currency: UK Pound GBX
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.